[Studies on the safety and immunogenicity of lyophilized live attenuated measles-mumps-rubella combined vaccine].
OBJECTIVE
To study the safety and immunogenicity of the measles-mumps-rubella combined vaccine (MMR) produced by Beijing Biological Product Institute.


METHODS
Children aged 10-12 years, 2-2.5 years and 8-12 months were selected to be vaccinated with Beijing MMR vaccine (test vaccine). Other groups of children with similar nature were vaccinated with measles vaccine, mumps vaccine and rubella vaccine while using imported MMR vaccine (control vaccine) as controls.


RESULTS
The safety of the Beijing MMR vaccine was confirmed after vaccinating 32 children above 2 years old. Among 104 children of 8-12 months were vaccinated with Beijing MMR vaccine, only 6.7% of the children had transient fever and 1.9% had signs of rashes but with no other signs observed. The positive seroconversion rates of measles, rubella and mumps anti-HI were 100%, 100% and 85.7% respectively. GMT also showed high lever.


CONCLUSIONS
The MMR vaccine (Beijing) had good safety and immunogenicity which might be used to be the bases enhance immunization of measles.
Liu
Guohua
G
Henan Provincial Epidemic Prevention Station, Zhengzhou 450003, China.
Fang
Hanhua
H
Feng
Zijian
Z
Guo
Wanshen
W
Dong
Chunming
C
Zhang
Wenping
W
Ze
Wenyuan
W
D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002675:Child, Preschool; D005612:Freeze Drying; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D022542:Measles-Mumps-Rubella Vaccine / Q000009:adverse effects* / Q000276:immunology; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D022542:Measles-Mumps-Rubella Vaccine; D014613:Vaccines, Attenuated